Toukan Labs has successfully rolled out its OpenEyes platform across the Centre for Eye Research Australia (CERA), promising to significantly enhance the efficiency of research workflows and clinical trial management.
With over 3,800 participants across 80 clinical research studies, CERA and its subsidiary Cerulea Clinical Trials, operate an expansive research programme.
ToukanLabs said the OpenEyes electronic patient management platform will help manage this diverse patient cohort.
The rollout of OpenEyes at CERA included a comprehensive review of retrospective participation data to ensure quality and consistency throughout, while ensuring that research teams had the necessary training and resources to integrate it into their workflow, ToukanLabs said in a statement to mivision.
The rollout of OpenEyes at CERA included a comprehensive review of retrospective participation data to ensure quality and consistency throughout…
“CERA’s ophthalmologists and clinical trial coordinators have since further streamlined access to participant information including medical and ocular data, imaging, consents, and inbound correspondence, all within a single technology platform.
“OpenEyes also facilitates the generation of standardised letters while also tracking clinical trial participation, offering valuable metrics and key performance indicators, and allowing for more informed decisions around recruitment efforts,” the company said.
ToukanLabs said OpenEyes would also allow tracking of participants across multiple research studies.
“People who express interest but are not eligible for a current trial can be placed on a future recruitment register, with their consent. This ensures that participants can be allocated to new treatments or observational studies as they become available, maximising clinical trial reach and opportunities.”
ToukanLabs said the platform’s audit and security features align with data governance best practices.
